Schroder Ventures to fund only companies targeting middle class
By Venkatachari Jagannathan | 04 Sep 2000
"Our Indian focus is on companies whose products are directly used by the burgeoning middle class in India," declares Mr. Deepak Vaidya, country head, India, Schroder Capital Partners (Asia) Ltd. Industries that qualify under this classification are pharmaceutical, healthcare, retail and the like. "Segments like agriculture, steel, cement, infrastructure and even dot coms are out of our vision," he says.
According to him, Schroder Ventures has invested around $ 100 million in India out of its two Asia Pacific funds. He adds, "We haven’t concluded any major deals for our second fund, which has a corpus of $ 500 million."
Some of the Indian companies into which Schroder Ventures has put its money are Orchid Chemicals & Pharmaceuticals Ltd, Apollo Hospitals, Blue Dart. The Rs 175 crore investment in Orchid Chemicals is one of the biggest for the fund in the country. The investment has got the fund a berth in Orchid Chemicals'' board.
Though there is no lock-in period for its investment in Orchid Chemicals -- "We don’t accept any deals where there will be a lock-in period" -- Vaidya says that the fund sees Orchid Chemicals as a long term investment. It may be noted that Orchid Chemicals'' scrip, which went to dizzy heights to touch Rs 400-plus, came tumbling down after the union budget and after a not-so-inspiring performance last fiscal.
"Actually we are very much impressed with the Indian pharmaceutical industry as it has great potential for growth," says John Cheesmond, partner, Schroder Ventures Life Sciences Advisers (UK) Ltd, London, and a board member in Orchid Chemicals.
Interestingly, it seems Orchid Chemicals is charting its new growth plans upon the advice of Schroder Ventures. Says Mr Cheesmond, "The company has to consolidate its core activity in the bulk drug segment, get FDA approval for its plants to establish footprints in regulated markets and establish a formulation unit in India." And it is precisely this prescription that Orchid Chemicals is following.
Schroder Ventures, with its contacts in the pharmaceutical industry worldwide, is trying to locate a global partner for Orchid Chemicals in its endeavours, including doing contract research and global marketing of its products.
Latest articles
Featured articles
The $250 billion pivot: how 2026 became the year AI paid the rent
By Cygnus | 18 Feb 2026
2026 marks the shift from AI “promise” to “profitability.” Explore how India’s sovereign compute and Infosys’s revenue metrics are defining a $250B market pivot.
The analog antidote: perception, reality, and the "Windows crisis" narrative
By Cygnus | 17 Feb 2026
Viral claims of a Windows collapse contrast with market data showing a slower shift as enterprises weigh AI, hardware costs, and legacy systems.
The analog antidote: why Americans are trading algorithms for physical media
By Cygnus | 16 Feb 2026
Vinyl, books, and DVDs are seeing renewed interest as Americans seek ownership, focus, and a break from screen fatigue in an increasingly digital world.
China opens market to 53 African nations in zero-tariff pivot
By Cygnus | 16 Feb 2026
China will grant zero-tariff access to 53 African nations from May 2026, reshaping global trade ties and deepening economic links across the Global South.
The deregulation “holy grail”: Trump EPA dismantles the legal bedrock of climate policy
By Cygnus | 13 Feb 2026
The Trump EPA moves to rescind the 2009 Endangerment Finding, reshaping federal climate authority and business risk.
Tokenising the gilt: what the UK’s digital bond pilot could mean for sovereign debt
By Cygnus | 12 Feb 2026
HM Treasury selects HSBC Orion and Ashurst LLP for its Digital Gilt Instrument (DIGIT) pilot. A deep dive into the architecture, legal framework, and the shift toward near real-time settlement.
The silicon-rich AI race: how Cisco’s G300 puts networking at the center of compute
By Cygnus | 11 Feb 2026
Cisco's new Silicon One G300 targets AI data center bottlenecks as networking becomes central to compute performance.
Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains
By Cygnus | 06 Feb 2026
Intel and AMD server CPU shortages are hitting China as AI data center demand surges, pushing lead times to six months and driving prices higher.
Budget 2026-27 Seeks Fiscal Balance Amid Rupee Volatility and Industrial Stagnation
By Cygnus | 02 Feb 2026
India's Budget 2026-27 targets fiscal discipline with record capex as markets tumble, the rupee weakens and manufacturing struggles to regain momentum.


